Board of Directors
The Arbor Board is comprised of several individuals that have founded, created, and led Pharmaceutical companies ranging in value from several hundred million to over six billion dollars in market value. Arbor has the management team, products, and development projects needed to create the foundation for a strong, sustainable pharmaceutical company that will continually find ways to improve the lives of our patients.
Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, the advisor for five investment partnerships with $800 million in assets. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceutical sector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor's degree in Pharmacy.
Allen Chao, Ph.D.
Allen Y. Chao is a scientist turned businessman who founded Watson Pharmaceuticals and served as Chief Executive Officer from 1984 to 2008 and Chairman. He spent his childhood in Taiwan. Chao went to Taipei Medical College, where he graduated with a B.S. degree in Pharmacy in 1967. After immigrating to the United States, Chao obtained an M.S. degree in Pharmaceutics from West Virginia University in 1970. He subsequently received a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1973. In May 2000, Chao received an honorary D.Sc. degree from Purdue University in recognition of his leadership and vision for the production and marketing of pharmaceutical products. Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Allergan plc), a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. At the time of his retirement from Watson the company had revenue of approximately $3 billion a year and it had three business units: Generic Pharmaceuticals, Branded Pharmaceuticals, and Distribution. While at Watson, Dr. Chao oversaw the company's growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao is currently the Chief Executive Officer of Tanvex BioPharma, Inc., a Taiwan-based company listed on the Taiwan Stock Exchange Corporation principally engaged in the research, development and manufacture of biosimilars.
Emily Janvey (Menlo Park) is a member of the Health Care industry team within KKR's Private Equity platform. Prior to joining KKR, Dr. Janvey was with OrbiMed and TPG where she provided non-dilutive capital solutions to healthcare companies and institutions. Prior to investing, Dr. Janvey was a consultant at McKinsey and Company in the healthcare vertical. She holds a B.A. in neuroscience, summa cum laude, from Hamilton College and an M.D. and M.B.A from The University of Pennsylvania’s Perelman School of Medicine and Wharton School respectively.
Jason Klarreich is the Chief Operating Officer at JW Asset Management, LLC, a registered investment advisor based in New York City. JWAM is the advisor to five investment partnerships with combined assets under management in excess of $800 million. Mr. Klarreich has worked at JWAM since 2006, where he is responsible for financial reporting, compliance, and oversight of the private equity practice. Prior to joining JWAM, Mr. Klarreich worked at Morgan Stanley Smith Barney as a financial analyst, and later a senior vice president and risk manager at Heartland Securities. He is a graduate of Emory University where he received a bachelor’s degree in business with a concentration in finance.
Ali Satvat is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. He leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment Committee and the Health Care Strategic Growth Portfolio Management Committee. He currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Cohera Medical, Coherus BioSciences, PRA Health Sciences, Slayback Pharma and Trilogy MedWaste. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care and was actively involved with many of the firm’s successful private equity and growth equity investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat is a member of the board of directors of the Healthcare Private Equity Association.
Chief Executive Officer
Ed Schutter has over thirty years of pharmaceutical industry experience and was previously President of Sciele (Shionogi) Pharmaceuticals prior to joining Arbor. Prior to Sciele, Ed served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, GA. Ed is a registered pharmacist with a degree in Pharmaceutical Sciences from Mercer University and an MBA from Kennesaw State University. He is currently a board member of Vitruvias Therapeutics, Vensun Pharmaceuticals, Establishment Labs, and Mercer University.